COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00199368
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : July 13, 2016
Kyowa Hakko Kirin UK, Ltd.
Information provided by:
Kyowa Kirin Pharmaceutical Development, Inc.

Brief Summary:
This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Drug: Istradefylline ( KW-6002) Phase 3

Detailed Description:
Patients with Parkinson's disease with motor complications on levodopa therapy who completed the prior double-blind studies 6002-EU-007, 6002-US-013 or 6002-US-018 are eligible to enter into this 1-year, long-term open safety study with a starting istradefylline dose of 40mg per day.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 1100 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Long-Term, Multicenter, Open-Label Safety Study With Oral 20 or 40 mg/d Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.
Study Start Date : October 2004
Actual Primary Completion Date : March 2007
Actual Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Safety

Secondary Outcome Measures :
  1. Safety

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Completion of study 6002-EU-007, 6002-US-013 or 6002-US-018
  • Non-pregnant and either not of childbearing potential or using specified contraception

Exclusion Criteria:

  • History of psychotic illness
  • Variant/atypical Parkinson's disease
  • Cancer within 5 years of enrollment
  • ALT/AST levels > 1.5 times ULN
  • Seizure disorder
  • Neuroleptic malignant syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00199368

Layout table for location information
United States, New Jersey
Kyowa Pharmaceutical Inc.
Princeton, New Jersey, United States, 08540
Sponsors and Collaborators
Kyowa Kirin Pharmaceutical Development, Inc.
Kyowa Hakko Kirin UK, Ltd.
Layout table for investigator information
Study Director: Neil Sussman, MD Kyowa Kirin Pharmaceutical Development, Inc.
Layout table for additonal information Identifier: NCT00199368    
Other Study ID Numbers: 6002-INT-001
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: July 13, 2016
Last Verified: July 2016
Keywords provided by Kyowa Kirin Pharmaceutical Development, Inc.:
Parkinson's disease
end of dose wearing off
OFF time
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Adenosine A2 Receptor Antagonists
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs